Bisaryl amides as NRF2 activators

A compound of Formula (I)

• wherein:
• B is benzotriazolyl, phenyl, triazolopyridinyl, —O—(CH2)-triazolyl, or —(CH2)2-triazolyl, wherein each of benzotriazolyl, phenyl, triazolopyridinyl, —O—(CH2)-triazolyl, or —(CH2)2-triazolyl is unsubstituted or substituted by 1, 2, or 3 substituents independently selected from —C1-3alkyl, —C3-7cycloalkyl, —O—C1-3alkyl, —CN, —(CH2)2—O—(CH2)2—OR3 and halo;
• D is —C(O)—NR4R5, —NR4—C(O)—R5, —NR3—C(O)—NR4R5, or —NR4—C(O)—O—R5;
• R1 is hydrogen, —C1-3alkyl, F, oxetanyl, or the two R1 groups together with the carbon to which they are attached form a cyclopropyl group;
• R2 is hydrogen, methyl, —CF3, or halo;
• R3 is hydrogen or —C1-5alkyl;
• R4 is hydrogen or —C1-5alkyl;
• R5 is hydrogen, —C1-5alkyl, —C3-7cycloalkyl, —C4-8heterocycloalkyl, —C1-5alkoxy, —C1-3alkyl-O—C1-3alkyl, —C1-3alkyl-NH—C1-3alkyl, —C1-3alkyl-NH—C(O)R3, —C1-3alkyl-SO2C1-3alkyl, —C1-3alkyl-C4-8heterocycloalkyl, —C1-3alkyl-C(O)NR3R4, aryl, —C1-5alkylheteroaryl, or heteroaryl, wherein each of —C1-5alkyl, —C3-7cycloalkyl, —C1-5alkoxy, —C1-3alkyl-O—C1-3alkyl, —C1-3alkyl-NH—C1-3alkyl, —C1-3alkyl-C(O)NR3R4, aryl, —C1-5alkylheteroaryl, or heteroaryl is unsubstituted or substituted by one or two substituents independently selected from —C1-3alkyl, —C1-3alkylaryl, —C1-3alkylheteroaryl, aryl, —C1-3alkylC(O)R3, —C1-3alkylC(O)OH, —C1-3alkylNHC(O)OR4, —C1-3alkylOSi(R3)3, —C1-3alkylOH, —C1-3alkylNH2, —SCH3, —C4-8heterocycloalkyl (optionally substituted with R3), —NH—(CH2)n-CH—(OH)2, —O—CH2—CH—(NH2)—CH2—OH, —SO2R3, —SO2NR3R4, —OH, —C1-3alkoxy, oxo, —CO2H, —C(O)NR3R4, —C(O)OR3, —NH—C(O)—C1-3alkyl, F, Cl, —CN, —CH—F2, —CF3, —(CH2)n—O—(CH2)m—CH3, —O(CH2)n—OH, —O(CH2)nC(O)OR3, —O(CH2)nOR3, —O(CH2)nNHC(O)OR3, —O(CH2)nNH2, —C3-7cycloalkyl, and a 5-6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, N and S;
• or R4 and R5 together with the nitrogen atom to which they are attached form a 5-8-membered heterocyclic ring, an 8-11-membered bicyclic heterocyclic ring or a 9-10-membered bridged bicyclic heterocyclic ring, wherein each 5-8-membered ring, 8-11-membered bicyclic ring, or 9-10-membered bridged bicyclic ring optionally includes one —C(O) or one —S(O)2, and wherein each 5-8-membered ring, 8-11-membered bicyclic ring, or 9-10-membered bridged bicyclic ring optionally independently contains one, two or three oxygen ring atoms, one, two or three sulfur ring atoms or one, two or three nitrogen ring atoms, and wherein each 5-8-membered ring, 8-11-membered bicyclic ring, or 9-10-membered bridged bicyclic ring is unsubstituted or substituted by one, two or three substituents independently selected from —C1-5alkyl, —C3-7cycloalkyl, —C4-7heterocycloalkyl, —(CH2)phenyl, halogen, —NR3R4, —CHF2, —CF3, and —(CH2)n—O—(CH2)m—CH3;
• Linker is —CH2—, —CH2—N(-cyclopropyl)-CH2—, —CH2—N(CH3)—CH2— or —N—(CH3)—CH2—;
• A is
• Y is independently selected from N or CH;
• Z is O or CH2;
• R6 is independently selected from hydrogen or —C1-4alkyl;
• wherein A is unsubstituted or substituted with one, two or three substituents independently selected from halo, —CF3, —C1-4alkyl, —CN, —OMe, —C(O)NH2, —OCF3, —C1-4alkylNR8R9;
• R8 is hydrogen or —C1-4alkyl;
• R9 is —C1-3alkyl, aryl, heteroaryl, —C(O)C1-3alkyl, —SO2C1-3alkyl, —C(O)aryl, —C(O)heteroaryl, —SO2aryl, —SO2heteroaryl, —C3-7cycloalkyl, —C1-3alkylC3-7cycloalkyl, —C1-3alkylC3-7heterocycloalkyl, —C1-3alkylheteroaryl or —C1-3alkylaryl, wherein each of —C1-3alkyl, aryl, heteroaryl, —C(O)C1-3alkyl, —SO2C1-3alkyl, —C(O)aryl, —C(O)heteroaryl, —SO2aryl, —SO2heteroaryl, —C3-7cycloalkyl, —C1-3alkylC3-7cycloalkyl, —C1-3alkylC3-7heterocycloalkyl, —C1-3alkylheteroaryl or —C1-3alkylaryl is unsubstituted or substituted by 1, 2 or 3 substituents independently selected from halo, —CN, —CF3, —OCF3, —OCH3, —C1-3alkyl, —OC1-3alkyl, —OC3-7cycloalkyl, —OC3-7hetercycloalkyl, —O-aryl and —O-heteroaryl;
• X is independently CH or N;
• m is 1, 2 or 3;
• and
• n is 1, 2 or 3;
• or a pharmaceutically acceptable salt thereof.